Year end report 2003
Tripep AB (publ)-Year-end Report 2003 · Loss after tax for the full year 2003: SEK -13.0 million (SEK - 42.5 m). Research and development costs for the full year 2003: SEK 12.4 million (SEK 13.8 m). The company has yet to generate any operating income, and accordingly has no net sales. EPS for the full year 2003: SEK -1.00 (-3.07). · Research associated with GPG's metabolite (previous working title: MetaboliteX = 'Metabolite Unknown') has resulted in the discovery of the antiviral substance alfaHGA, and a patent application has been filed for its structure. A chemical synthesis method has